Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 1999

View Archived Issues

BCH-2763 shows antithrombotic activity in canine model of DVT

Bio-Rad finalizes acquisition of Pasteur Sanofi Diagnositics

Genome Therapeutics reaches milestone in antifungal alliance with Schering-Plough

Phase I/II results support further development of Leuvectin

Progenics' PRO-140 shown to be potent HIV inhibitor

Schein to license proprietary chelating compound from SunPharm

Duramed and Solvay team up to promote hormone products

Anesta licenses Actiq rights to Elan

AEterna accelerates clinical development of AE-941

Cantab licenses anti-OX40 antibodies to Celltech

FDA gives go-ahead for phase II clinical trial of ML Laboratories' AIDS treatment

Solvay launches Aceon tablets in the U.S. for 24-hour control of hypertension

FDA advisory committee to review Visudyne NDA

New MMP inhibitors from Leo reportedly superior to structurally related compounds

Apotex describes new inhibitors of cysteine proteases in recent patent literature

NC-100100 is safe and well tolerated in target group of patients

Steroid antibacterials with the added ability to increase susceptibility to other antibiotics

FDA approves seven-day HRT patch

Searle's new amino acid derivatives preferentially inhibit iNOS

Extensive coverage of ABT-773, a novel ketolide, at the ICAAC meeting

Timetable for creation of Aventis revealed this week

Japanese researchers isolate and characterize two related immunosuppressants

Licensing opportunity from NIH: calcium channel modifiers with application in HIV and AIDS

Immunostimulatory oligonucleotide enhances immune response to HBV vaccine in animals

Sepracor obtains rights to develop hypnotic agent in U.S.

PMS-601: a PAF antagonist with potential as a new adjuvant AIDS therapy

Synthesis and activity of potent, selective sigma1 ligands reported by Taisho

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...